Last reviewed · How we verify
MK0657
At a glance
| Generic name | MK0657 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of MK0657 in Parkinson's Disease Patients (0657-006) (PHASE1)
- Antidepressant Effects of NR2B in Major Depression (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0657 CI brief — competitive landscape report
- MK0657 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI